D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population.

Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has suffered a setback as the therapy ...

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...

The wet AMD market exceeds $12 billion ... minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspension ...

Since my June 2024 article on them, the company has focused on its flagship drug candidate called “Axpaxli.” For context, Axpaxli is intended for wet AMD as an injection every six to 12 months.

Wet AMD remains the leading cause of vision loss ... The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant ...